US2021277116A1PendingUtilityA1

Native human antibodies for immune checkpoint modulation targets tim-3 and b7-h3

61
Assignee: TRELLIS BIOSCIENCE LLCPriority: Jan 3, 2017Filed: May 24, 2021Published: Sep 9, 2021
Est. expiryJan 3, 2037(~10.5 yrs left)· nominal 20-yr term from priority
Inventors:Angeles EstellesMikhail GishizkyStefan RyserLawrence M. Kauvar
A61P 35/00C07K 2317/24C07K 2317/31C07K 2317/92C07K 2317/54C07K 2317/565C07K 16/30C07K 2317/55C07K 16/2803C07K 2317/21C07K 16/2827C07K 2317/56
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Novel monoclonal antibodies directed against immune checkpoint modulator (ICM) proteins TIM-3 and B7-H3 are useful in treating cancer and immune system disorders.

Claims

exact text as granted — not AI-modified
1 . An isolated nucleic acid or isolated nucleic acids that separately or in combination encode a recombinantly produced monoclonal antibody (mAb) or effective antigen-binding
 portion thereof, which includes the CDR regions of TRL6042, TRL6061, TRL10006, TRL6099, TRL6120 or TRL4542.   
     
     
         2 . The nucleic acid or nucleic acids of  claim 1  coupled to control sequences for expression. 
     
     
         3 . The nucleic acid or nucleic acids of  claim 2  contained in a vector. 
     
     
         4 . Host cells containing a vector of  claim 3 .

Join the waitlist — get patent alerts

Track US2021277116A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.